CRDM is next guys....
Please note that (STJ) St Jude Medical is a competitor to VASO.
hoovers.com
CRDM signed a distribution agreement with them.
biz.yahoo.com
The Cardiology conference is being held this weekend. Already, news is beginning to trickle out concerning the conference, about who is presenting what, and the new therapies for cardiovascular disease. I fully expect CRDM to have it's run amongst it's brethren such as VASO and IDYN. Should CRDM takes out it's 52 week high of 4, there's no telling where it might end up.
Current trading prices:
CRDM $3 1/2
IDYN $9 1/2
VASO $12
acc.org
Stocks to watch:
CRDM, BSX, BCR, JNJ, VASO, ABMD, GDT, MDT, JTJ.
My 2 biggest plays on this list are CRDM and VASO.
CRDM.....Cardima, Inc. designs, develops, manufactures and
markets minimally invasive, single-use, microcatheter-based
systems for the mapping and ablation of the two most comnon
forms of cardiac arrhythmias: atrial fibrillation and
ventricular tachycardia.
CRDM has a float of only 3.3mil and has many eyes on it. Trading currently @ $3 1/2. Large blocks were bought in
the $ 2 1/2-3/4 range last week. They have just recently formed a distribution agreement with St Jude Medical (STJ)for their micro catheters. Also STJ, currently trading @ $26, has taken a minority stake in Cardima. CRDM's 52 week high is 4.
VASO.... is engaged in the commercialization
of the enhanced external counterpulsation (EECP) system, a
computer-based medical device for the non-invasive,
atraumatic treatment of patients with coronary artery
disease. For the 6 months ended 11/30/99, revenues totaled
$6M, up from $792K. Net income applicable to Common
totaled $324K vs. a loss of $3.9M. Results reflect an
increase in the number of EECP providers.
IDYN....designs, develops, manufactures and markets
minimally invasive surgical access products incorporating
its proprietary radial dilation technology. For the 9
months ended 9/99, revenues rose 13% to $14.8M. Net
income totaled $917K, up from $141K. Revenues reflect
increased unit sales of the company's Step devices. Earnings
reflect a reduction in R&D expenditures due to a transfer
of the EnAbl thermal ablation program to US Surgical.
*PRELIMINARY: For the 3 months ended 12/31/1999, revenues
were 5,608; after tax earnings were 563.
|
